Abstract Immunotherapy with programmed death 1 (PD-1)-and programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic landscape for several types of malignancy. PD-1 and PD-L1 are immune checkpoint proteins whose binding ultimately result in T cell exhaustion and self-tolerance. Blocking this pathway 'releases the brakes' on the immune system and allows for attack of tumor cells that express PD-L1. The clinical trials that led to the US Food and Drug Administration (FDA) approval of these agents used different immunohistochemical (IHC) platforms with various PD-L1 antibodies to assess for PD-L1 expression on either tumor cells or tumor-infiltrating immune cells. There are four PD-L1 IHC assays registered with the FDA, using four different PD-L1 antibodies (22C3, 28-8, SP263, SP142), on two different IHC platforms (Dako and Ventana), each with their own scoring systems. Attempts at harmonization of PD-L1 IHC antibodies and staining platforms are underway. While PD-L1 IHC can be used to predict the likelihood of response to anti-PD-1 or anti-PD-L1 therapy, a proportion of patients that are negative can have a response and identification of alternative biomarkers is critical to further refine selection of patients most likely to respond to these therapies.
Introduction
Immunotherapy with programmed death 1 (PD-1)-and programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic landscape for several types of malignancy. PD-1 is a receptor present on the surface of activated T and B cells and binds to its ligands PD-L1 and programmed death-ligand 2 (PD-L2). PD-L1 is found on many normal tissues, including placenta, vascular endothelium, epithelium, muscle, and pancreatic islet cells, as well as on B cells, T cells, and macrophages, among other cell types [1] . The binding of PD-1 to PD-L1 induces a pathway that acts to inhibit the cytotoxic/cytolytic effector functions of T lymphocytes, a process also termed T cell exhaustion. This is an important auto-regulatory response to local inflammation such that local tissues do not get damaged as & Liza C. Villaruz villaruzl@upmc.edu bystanders in the immune response [2] . PD-L1 is also expressed on the surface of tumor cells, some of which have found ways to upregulate PD-L1 expression, leading to suppression of the host immune response and tolerance to tumors. It thus follows theoretically that suppressing the PD-1/PD-L1 pathway would 'release the breaks' and induce an immune system attack on tumor cells. The ultimate goal is improved overall survival (OS), which has been demonstrated in multiple clinical trials across multiple disease sites.
Immune checkpoint inhibitors were first approved in melanoma, specifically ipilimumab (cytoxic T lymphocyte antigen 4 inhibitor, Bristol-Myers Squibb) which received US Food and Drug Administration (FDA) approval in March 2011. In September 2014 the first anti-PD-1 antibody, pembrolizumab (Merck) was approved by the FDA for use in metastatic melanoma. Since then, therapeutic monoclonal antibodies that target either PD-1 or PD-L1 have been FDA approved for use in non-small cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, head and neck cancer, Merkel cell carcinoma, Hodgkin lymphoma, gastric cancer, hepatocellular carcinoma, and microsatellite instability-high cancer regardless of histology, with approval pending in other diseases. Interestingly, the only setting where PD-L1 positivity is specified in the FDA approval as a precondition to therapy with a PD-1/ PD-L1 antibody is pembrolizumab in the treatment of NSCLC.
Early studies in multiple cancer types have shown improved outcomes in patients treated with anti-PD-1 antibodies whose tumors are found to have PD-L1 expression, prompting further investigation of PD-L1 as a predictive biomarker for PD-1 response despite PD-1 having multiple other ligands. In the phase I study of nivolumab (anti-PD-1 antibody; Bristol-Myers Squibb) in multiple cancer types, the murine antihuman PD-L1 monoclonal antibody 5H1 was used to evaluate pretreatment tumor specimens from 42 patients. In this study, PD-L1 positivity was defined by 5% or more of tumor cells. None of the 17 patients that had PD-L1 negative tumors had an objective response, while nine of 25 (35%) patients with PD-L1-positive tumors had a response [3] . A group evaluating immunohistochemical (IHC) features in patients with melanoma, NSCLC, renal cell carcinoma, colorectal carcinoma, or prostate cancer on the phase I nivolumab trial, including PD-1, PD-L1, and PD-L2 expression as well as patterns of immune cell infiltration and lymphocyte subpopulations, assessed 41 pretreatment tumor specimens and found that of the evaluated features, it was tumor PD-L1 expression that correlated the most with objective response to anti-PD-1 therapy [4] . The PD-L1 monoclonal antibody 5H1 was again used in this study [4] but was later abandoned in favor of a commercial assay developed by Dako using rabbit anti-human clone 28-8. There are four PD-L1 IHC assays registered with the FDA, using four different PD-L1 antibodies (22C3, 28-8, SP263, SP142) on two different IHC platforms (Dako and Ventana), each with their own scoring systems. Varying antibody clones and platforms have been approved for each available PD-1 and PD-L1 inhibitor, making comparison amongst trials difficult. This review focuses on the trials leading to the approval of PD-1 and PD-L1 inhibitors in NSCLC, with a specific focus on how PD-L1 expression correlates with response and review issues related to determination of PD-L1 status and refinement of patient selection for PD-1-/PD-L1-directed therapy. We also discuss harmonization studies evaluating the interchangeability of the assays as well as potential alternative biomarkers of response to immunotherapy.
Programmed Death 1 (PD-1) Inhibitors
Pembrolizumab (anti-PD-1 antibody; Merck) and nivolumab are FDA approved for use in previously treated metastatic NSCLC, and pembrolizumab is also FDA approved for use in the first-line setting in patients with PD-L1 expression greater than 50% and in combination with carboplatin/pemetrexed in the first-line setting regardless of PD-L1 status.
Second-Line Treatment

Nivolumab
CheckMate 017, the phase III trial of nivolumab versus docetaxel in previously treated squamous NSCLC, evaluated PD-L1 with an automated IHC assay (Dako) and a rabbit monoclonal antihuman PD-L1 antibody, clone 28-8 (Epitomics), with samples classified as positive when staining of the tumor cell membrane was observed at prespecified expression levels of 1, 5, or 10% [5] (see Table 1 ). Similar rates of objective responses were seen in patients regardless of PD-L1 status, with PD-L1 expression being neither prognostic nor predictive of any of the efficacy endpoints [5] . In contrast, in CheckMate 057, the phase III trial of nivolumab in previously treated nonsquamous NSCLC that used the 28-8 clone and Dako IHC, there was an advantage in the PD-L1-positive patients treated with nivolumab, with nearly double the median OS in patients with at least 1% PD-L1 positivity treated with nivolumab as compared with docetaxel [6] . There were no meaningful differences in OS between the nivolumab and docetaxel groups when looking at patients who were PD-L1 negative [6] . The authors concluded that despite the PD-L1 Testing in PD-1/PD-L1 Inhibitor Therapy in Lung Cancer lack of improvement in OS between nivolumab and docetaxel in non-squamous PD-L1-negative patients compared with docetaxel, nivolumab remains a reasonable treatment option given its improved safety profile and the durability of responses when they do occur [6] . Indeed, nivolumab is FDA approved for use in metastatic NSCLC in the secondline setting, regardless of PD-L1 expression. The 2-year update of CheckMate 017 and CheckMate 057 confirmed a greater magnitude of benefit in non-squamous NSCLC patients that were PD-L1 positive and treated with nivolumab, whereas PD-L1 expression was neither predictive nor prognostic in squamous NSCLC patients [7] . The pembrolizumab KEYNOTE trials did not include subgroup analysis data looking at PD-L1 positivity and response by histology [8] [9] [10] [11] .
Pembrolizumab
The phase Ib study of pembrolizumab in the treatment of advanced NSCLC, KEYNOTE 001, used the anti-PD-L1 antibody clone 22C3 (Merck) to assess PD-L1 expression at various levels, with positivity defined by membranous staining in at least 1% of cells within tumor nests [8] . PD-L1 staining of at least 50% correlated with improved efficacy of pembrolizumab [8] . Based on data from KEYNOTE 001, pembrolizumab was approved by the FDA in October 2015 for use in patients with metastatic NSCLC who have progressed after first-line treatment and with PD-L1-positive tumors as assessed by 1% staining using the companion diagnostic PD-L1 IHC 22C3 pharmDx test. Long-term follow-up data from KEY-NOTE 001 revealed that OS increased with an increasing PD-L1 tumor proportion score [19] . In the phase II/III trial of pembrolizumab versus docetaxel, KEYNOTE 010, all patients had PD-L1 expression of at least 1% of tumor cells, which was assessed using the 22C3 antibody and Dako IHC [9] . In the general patient population, OS was significantly longer for patients treated with pembrolizumab than those treated with docetaxel [9] . The subset of patients with at least 50% staining for PD-L1 had significantly longer OS with pembrolizumab versus docetaxel, as well as significantly longer progression-free survival (PFS) [9] . KEYNOTE 010 data were further analyzed by PD-L1 expression of various levels, with staining of 1-24, 25-49, 50-74 and C 75% [20] . In the patients treated with pembrolizumab, OS, PFS, and objective response rate (ORR) generally increased along with increasing PD-L1 expression, with the longest OS and PFS and highest ORR in patients with PD-L1 expression C 75% of tumor cells [20] .
First-Line Treatment
Nivolumab
In CheckMate 012, a phase I multicohort trial of nivolumab in the first-line setting, PD-L1 expression was assessed using a validated IHC assay (Dako) with the 28-8 clone, with positivity defined as at least 1% of tumor cells [21] . In the cohort of patients treated with combination nivolumab and platinum-based doublet chemotherapy, there was no association between PD-L1 expression and OS or PFS, with equivalent responses seen across PD-L1 expression levels [21] . In the cohort of patients treated with nivolumab monotherapy, clinical activity was observed regardless of PD-L1 expression, with higher ORRs in patients with higher PD-L1 expression [22] . However, CheckMate 026, a phase III trial of nivolumab in the firstline setting, demonstrated no difference in PFS between the nivolumab and chemotherapy groups even among patients that had greater than 5% PD-L1 expression [12, 13] . Nivolumab is not FDA approved in the first-line setting.
Pembrolizumab
In a phase III trial in the first-line setting, pembrolizumab was shown to significantly improve OS and PFS as compared to platinum-based chemotherapy in patients with over 50% expression of PD-L1 as assessed by the 22C3 pharmDx IHC assay (Dako) [10] . As a result of this trial, in October 2016 pembrolizumab was approved in the first-line setting for patients with greater than 50% PD-L1 expression. One can postulate that the difference in the first-line pembrolizumab trial meeting its primary endpoint and not the first-line nivolumab trial is related to patient selection. In the phase II study of carboplatin and pemetrexed with or without pembrolizumab for non-squamous NSCLC in the first-line setting, there was a difference in the primary endpoint of ORR-55% in the pembrolizumab and chemotherapy group versus 29% in the chemotherapy group-as well as a difference in PFS of 13.0 versus 8.9 months, respectively [11] . Exploratory analyses found similar rates of ORR regardless of PD-L1 expression [11] . These data suggest increased efficacy of combining cytotoxic therapy with PD1/PD-L1 inhibitors above that of chemotherapy alone. As a result of this trial, pembrolizumab in combination with carboplatin/pemetrexed was approved by the US FDA in May 2017 for use in metastatic non-squamous NSCLC in the first-line setting regardless of tumor PD-L1 expression. A confirmatory phase III clinical trial is underway.
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab is a humanized IgG1 monoclonal anti-PD-L1 antibody (F Hoffmann-La Roche/Genentech) that was FDA approved for use in previously treated metastatic NSCLC regardless of PD-L1 status, based on the results of two international, randomized trials: POPLAR and OAK. In POPLAR, the phase II study of atezolizumab versus docetaxel, PD-L1 expression on both tumor and tumorinfiltrating immune cells was assessed using the Ventana SP142 IHC assay (Ventana Medical Systems, Tucson, AZ, USA) [14] . Tumor cells expressing PD-L1 were scored as a percentage of total tumor cells (TC3 C 50%, TC2 C 5% and\ 50%, TC1 C 1% and\ 5, and TC0\ 1%) and tumor-infiltrating immune cells were scored as a percentage of tumor area (IC3 C 10%, IC2 C 5% and\10%, IC1 C 1% and\5%, and IC0\ 1%) [14] . There was an OS benefit in patients treated with atezolizumab and increasing improvement in OS correlated with PD-L1 IHC expression on tumor cells and tumor-infiltrating immune cells [14] . OS in patients with TC0 and IC0 PD-L1 status in the atezolizumab group was similar to the docetaxel group [14] . Long-term follow-up of POPLAR reveals an improvement in median OS in the atezolizumab group versus docetaxel in almost every subgroup of PD-L1 expression, except in the TC0 and IC0 group where median OS was the same [23] . In OAK, the phase III trial of atezolizumab versus docetaxel, there was an OS benefit among patients treated with atezolizumab, with median OS of 13.8 versus 9.6 months [16] . This benefit was seen regardless of PD-L1 expression and even in patients with less than 1% PD-L1 expression, who had a 25% improvement in OS with atezolizumab as compared to docetaxel [24] . PD-L1 expression was assessed on both tumor cells and tumor-infiltrating cells with the Ventana SP142 assay [16] . Avelumab (Pfizer) is a human IgG1 monoclonal antibody PD-L1 inhibitor. In the phase Ib trial (JAVELIN Solid Tumor) investigating avelumab in previously treated patients with metastatic or recurrent NSCLC, PD-L1 expression on tumor and immune cells was assessed using a Dako assay with a rabbit monoclonal antibody clone 73-10 [18] . Tumor cell staining was assessed at prespecified levels of C 1%, C 5%, C 5%. Immune cells were considered to stain positive for PD-L1 at C 10% and were assessed in hotspots [18] . Neither the proportion of patients with objective response nor OS outcomes differed between PD-L1-positive and -negative patients at any prespecified expression level [18] .
Durvalumab (AstraZeneca), formerly MEDI4736, is a human IgG1 monoclonal antibody PD-L1 inhibitor. Phase I/II data in the third-line setting for patients with metastatic NSCLC revealed an ORR of 14% in the general population and 23% in PD-L1-positive patients [17] . PD-L1 was evaluated using the SP263 assay, with positivity defined as staining of 25% or more of tumor cells. Interestingly, ORR was higher in squamous (21%) than non-squamous (10%) patients [17] .
In most of the completed combination immunotherapy studies of PD-1/PD-L1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibodies, PD-L1 expression does not seem to correlate with outcomes in advanced NSCLC patients. In a phase I/II study of pembrolizumab plus ipilimumab (KEYNOTE 021, cohorts D and H), there was no link between PD-L1 status as determined by the 22C3 antibody and ORR or median OS [25] . In a phase Ib study of durvalumab plus tremelimumab (anti-CTLA-4 antibody; AstraZeneca), which assessed PD-L1 status with the Ventana SP263 assay, with samples considered positive if C 25% of tumor cells showed membrane staining, evidence of clinical activity was noted in both patients with PD-L1-positive -negative tumors [26] . However, in the phase I multicohort study of nivolumab plus ipilimumab (CheckMate 012), the combination had increased clinical activity in patients whose tumors express PD-L1, as determined by the 28-8 antibody [27] . The proportion of patients that achieved a response was near 90% in patients whose tumors had greater than 50% PD-L1 expression [27] . The currently ongoing phase III trial (ARCTIC study) of durvalumab with or without tremelimumab for previously treated patients with advanced NSCLC is assessing PD-L1 status with the SP263 assay [28] .
PD-L1 Assays
Assessing for PD-L1 expression in an attempt to predict response to PD-1 or PD-L1 inhibitor therapy is not as straightforward as one would imagine. There is no uniformity in PD-L1 assessment among the clinical trials that were performed to approve these agents. A different companion diagnostic antibody clone with its associated IHC platform was used for each approved anti-PD-1 or anti-PD-L1 inhibitor, and it is not clear how interchangeable these assays are. This is problematic when considering that hospital laboratories are then faced with the decision of which PD-L1 diagnostic IHC platform and clone to use given cost constraints. It may make the most clinical sense to carry the 22C3 assay that was approved for use with pembrolizumab, given this is the only agent that is approved in the setting of PD-L1 positivity in NSCLC only, whereas the other approved agents can be used regardless of PD-L1 expression. There is variability in the definition of 'PD-L1 positivity' in various trials and some studies included analysis of unevaluable samples with the PD-L1-negative tumors. There was also a difference in which cells were evaluated for PD-L1 expression, with some studies finding a correlation with response and tumor cell PD-L1 staining and some finding an association with response and a combination of tumor and tumor-infiltrating immune cell staining. Additionally, some trials required biopsy prior to enrollment, whereas others relied on archival tissue, which is problematic since PD-L1 expression is thought to change over time. For instance, PD-L1 expression was shown to be dynamically induced by interferon (IFN)-c in a mouse model in the melanoma tumor microenvironment [29] . There is also intra-tumor heterogeneity [30] , so a biopsy of one site at one point in time may not be the most appropriate biomarker.
Besides the variation in PD-L1 antibody and platform, there are other technical issues to consider with regards to PD-L1 testing. Assessing formalin-fixed tissue as compared to freshly frozen tissue can underestimate PD-L1 expression [31] . Gadiot et al. found a range of PD-L1 expression when assessing samples with multiple differing anti-PD-L1 antibodies in both formalin-fixed and freshly frozen tissue [31] . There is a paucity of data on PD-L1 testing in cytology preparations, which can be clinically problematic as this is the predominant sample type in some institutions [32] . Because there are only two small hydrophilic regions on PD-L1 that would be amenable for IHC detection, IHC antibodies typically bind PD-L1 at sites that are structurally unique compared with those of therapeutic PD-L1 antibodies [1] .
In a meta-analysis comparing PD-1/PD-L1 inhibitors to docetaxel in the second-line setting for treatment of advanced NSCLC, the benefit from PD-1/PD-L1 inhibitors was limited to the PD-L1[1% subgroup [33] . For PD-L1[1% patients versus PD-L1\1% patients treated with PD-1/PD-L1 inhibitors, the odds ratio of the ORR was 2.18 (95% confidence interval [CI] 1.45-3.29; p = 0.0002) [33] . In a separate meta-analysis including 1612 patients from 13 trials, the overall response rate was statistically significantly higher in the PD-L1 positive group (relative risk [RR] 2.06 [95% CI 1.50-2.83]) [34] . The authors concluded that PD-L1 overexpression can be considered a predictive biomarker for response to immune checkpoint inhibitors in NSCLC, independent of previous treatments or tumor histology [34] . A third meta-analysis including 6800 patients from 51 trials of PD-1/PD-L1 antibodies in various cancer types found that, as compared with tumors with negative PD-L1 expression, tumors with positive PD-L1 expression had a significantly higher clinical response rate (41.4 vs. 26.5%; RR 1.92 [95% CI 1.53-2.41; p\0.001]) [35] .
Attempts to standardize IHC assays are necessary to help formulate guidelines. In a public workshop in March 2015, the FDA, the American Society of Clinical Oncology (ASCO), and the American Association for Clinical Research (AACR) announced efforts aimed at harmonizing companion diagnostics across PD-1-/PD-L1-directed therapies, involving collaboration between pharmaceutical and diagnostic companies [36] . The Blueprint PD-L1 IHC Comparison Project is a collaboration between the International Association for the Study of Lung Cancer, the AACR, and four pharmaceutical companies (Bristol-Myers Squibb, Merck & Co. Inc., AstraZeneca, and Genentech/ Roche) [37] . The phase I feasibility study of Blueprint assessed 39 NSCLC tumors with four PD-L1 IHC assays (Dako 22C3, Dako 28-8, Ventana SP142, and Ventana SP263), with results showing comparable staining of the 22C3, 28-8, and SP263 assays [37] . The SP142 assay had fewer stained tumor cells and did not correlate as well [37] . Blueprint phase I also indicated that immune cell staining had greater variability than tumor cell staining [37] . In 14 of 38 samples (37%), a different classification would be made depending on which assay was used [37] , which would have obvious impacts on treatment selection. Nineteen of 38 samples (50%) were classified above the selected cutoffs of all assays (or as PD-L1 positive) [37] . Five of 38 samples (13%) were classified below the selected cutoffs of all IHC assays [37] .
A study evaluating 493 commercially available samples from NSCLC patients indicated good concordance between the Ventana SP263 assay, Dako 28-8 assay, and Dako 22C3 assay [38] . Specifically, there was an overall percentage agreement of greater than 90% across multiple expression cut-offs [38] . In a separate effort in lung cancer, the National Comprehensive Cancer Network (NCCN) is collaborating with Bristol-Myers Squibb to evaluate variability across assays, heterogeneity within samples, and concordance of pathologist interpretation [32, 39] . In France, the national health system is carrying out a validation study of PD-L1 expression using different antibodies and platforms in solid and hematologic tumors [32] . An early German effort at harmonization of PD-L1 IHC in pulmonary squamous cell and adenocarcinoma evaluated inter-observer concordance in two sets of 15 resection specimens [40] . Four clinical trial assays including 28-8, 22C3, SP142, and SP263 as well as two laboratory-developed assays were interpreted independently by nine pathologists [40] . Proportion scoring of PD-L1 positive carcinoma cells showed moderate inter-observer concordance coefficients for the six-step scoring system that was used as well as good concordance coefficients of the dichotomous proportion cut offs of C 1, C 5, C 10, and C 50% [40] . Scoring of immune cells yielded lower inter-observer concordance coefficients [40] . The 28-8 and 22C3 assays stained similar proportions of carcinoma cells in 12 of 15 cases [40] . SP142 stained fewer carcinoma cells than the other three assays in four of 15 cases [40] . Rimm et al. evaluated serial histologic sections of 90 archival NSCLC specimens using the Dako 28-8 assay, Dako 22C3 assay, Ventana SP142 assay, and the E1L3 N antibody on the Leica Bond platform [41] . The SP142 assay was found to be an outlier, detecting significantly less PD-L1 expression in tumor and immune cells [41] . The 22C3 assay also showed statistically significant lower staining than the 28-8 or E1L3 N assays, but this was only significant when using the mean of the pathologists' scores [41] .
Alternative Biomarkers
Other biomarkers that have been shown to correlate with PD-1 inhibitor efficacy include the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations [42] . Whole exome sequencing was used to examine non-synonymous mutation burden from two cohorts of patients treated with pembrolizumab, and higher non-synonymous mutation burden was associated with clinical activity of pembrolizumab [42] . In the discovery cohort of 16 patients, the median number of nonsynonymous mutations per sample was 302 in patients with durable clinical benefit versus 148 in patients without durable benefit of treatment with pembrolizumab [42] . Confirmed ORR and PFS were both higher in patients with high non-synonymous mutation burden [42] . In the validation cohort of 18 patients, the rates of patients with durable clinical benefit and PFS were also significantly greater in patients with high non-synonymous mutation burden [42] . The ORR in tumors with the molecular smoking signature was 56 versus 17% in tumors with never-smoking signatures [42] . Interestingly, while the molecular smoking signature did correlate with efficacy of pembrolizumab, self-reported smoking status did not [42] . Mutations in DNA repair and replication were found in responders with the highest mutation burden, including mutations in POLD1, POLE, and MSH2 [42] . An exploratory analysis of the phase III study of nivolumab versus platinum-based chemotherapy in the first-line setting (CheckMate 026) found that patients with high tumor mutation burden had a benefit in PFS with nivolumab treatment as compared with platinum-based chemotherapy [43] . In the neoadjuvant setting, mutation burden and neoantigen density were associated with deeper pathologic response to treatment with nivolumab in patients with early-stage resectable NSCLC [44] .
IFN-c mRNA expression has been shown to correlate with response to PD-L1 inhibitors, specifically durvalumab in the setting of advanced NSCLC as assessed in the phase I/II study revealing response rates of 33% (14 of 43) and 8% (six of 79) in IFN-c-positive and -negative patients, respectively [45, 46] . The numerically highest rates of response were seen in the combined IFN-c-positive and PD-L1-positive patients [45] . PD-L1 was assessed using the Ventana SP263 assay and samples were considered positive if 25% or more of cells were stained at any intensity [45] .
Gopalakrishnan et al. have studied oral and intestinal microbiome samples via 16S ribosomal RNA (rRNA) gene sequencing in patients with metastatic melanoma treated with anti-PD-1 therapy [47] . The authors found significant differences in the diversity and composition of the gut microbiome in patients that had a response according to RECIST criteria versus non-responders [47] . There were no clear differences in the oral microbiomes [47] . Immune profiling by an IHC panel demonstrated significantly increased immune infiltrates in baseline tumor samples of responders [47] .
The Society for Immunotherapy of Cancer recently reconvened the Immune Biomarkers Task Force, comprised of an international multidisciplinary panel of experts, with the ultimate goals of identifying biomarkers predictive of clinical outcomes and elucidating why some patients do not respond to immunotherapy [48] . The most recent meeting, Working Group 4, focused on the complexity of the tumor microenvironment as well as novel tools to aid in such broad analyses [48] .
Conclusion
Clinicians should be aware that while PD-L1 IHC can be used to predict the likelihood of response to anti-PD-1 or anti-PD-L1 therapy in certain patient populations, the association between PD-L1 expression and response is not straightforward, and a proportion of patients with PD-L1-negative tumors can derive benefit from treatment. There are four PD-L1 IHC assays registered with the FDA, using four different PD-L1 antibodies (22C3, 28-8, SP263, SP142), on two different IHC platforms (Dako and Ventana), each with their own scoring systems. Attempts to standardize IHC assays to further explore the clinical utility of PD-L1 testing are underway. While harmonization studies have given early indication that the 22C3, 28-8, and SP263 assays are comparable, data are needed regarding the interchangeability of the assays as it pertains to response. To improve patient selection, alternative biomarkers are needed.
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